Methodological Challenges in Determining Longitudinal Associations Between Anticholinergic Drug Use and Incident Cognitive Decline

ObjectivesTo compare the effect of using different anticholinergic drug scales and different models of cognitive decline in longitudinal studies. DesignLongitudinal cohort study. SettingOutpatient clinics, Quebec, Canada. ParticipantsIndividuals aged 60 and older without dementia or depression (n=102). MeasurementsUsing baseline and 1-year follow-up data, four measures of anticholinergic burden (anticholinergic component of the Drug Burden Index (DBI-Ach), Anticholinergic Cognitive Burden (ACB), Anticholinergic Drug Scale (ADS), and Anticholinergic Risk Scale (ARS)) were applied. Three models of cognitive decline (worsening of raw neuropsychological test scores, Reliable Change Index (RCI), and a standardized regression based measure (SRB)) were compared in relation to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for the onset of a new mild neurocognitive disorder. The consistency of associations was examined using logistic regression. ResultsThe frequency of identifying individuals with an increase in anticholinergic burden over 1year varied from 18% with the DBI-Ach to 23% with the ACB. The frequency of identifying cognitive decline ranged from 8% to 86% using different models. The raw change score had the highest sensitivity (0.91), and the RCI the highest specificity (0.93) against DSM-V criteria. Memory decline using the SRB method was associated with an increase in ACB (odds ratio (OR)=5.3, 95% confidence interval (CI)=1.1-25.8), ADS (OR=5.7, 95% CI=1.1-27.7), and ARS (OR=6.5, 95% CI=1.34-32.3). An increase in the DBI-Ach was associated with a decline on memory testing using the raw change score method (OR=4.2, 95% CI=1.8-15.4) and on the Trail-Making Test Part B using SRB (OR=2.9, 95% CI=1.1-8.0). No associations were observed using the DSM-V criteria or RCI method. ConclusionThe choice of different methods for defining drug exposure and cognitive decline will have a significant effect on the results of pharmacoepidemiological studies.